Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice
- 1 November 1989
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 57 (11) , 3434-3437
- https://doi.org/10.1128/iai.57.11.3434-3437.1989
Abstract
The ability of bacterial lipopolysaccharide (LPS) to enhance the toxicity of Shiga-like toxin II (SLT-II) was investigated in rabbits and mice. Rabbits were continuously infused with 0.5 50% lethal dose (LD50) of SLT-II per day. Rabbits that received a 30-micrograms/kg dose of LPS (0.02 LD50) on day 3 of infusion were significantly more likely to die than were rabbits receiving SLT-II only. Rabbits receiving SLT-II and a lower dose of LPS (3 micrograms/kg) did not die but lost an average 3.3% +/- 1.0% of initial body weight during the first 5 days of infusion, compared with weight gains of 4.2% +/- 0.6% and 17.1% +/- 0.9% for rabbits receiving only SLT-II or LPS, respectively. Rabbits that were pretreated with LPS 20 h before challenge with a single dose of SLT-II showed highly significant protection from both the diarrheagenic and lethal effects of SLT-II. Pretreatment of endotoxin-responsive C3H/HeN mice protected the animals from challenge with an LD50 but not an LD100 of SLT-II. LPS enhanced the lethal toxicity of SLT-II for C3H/HeN mice when it was given at 8 or 24 h but not 0 or 72 h after SLT-II challenge. LPS did not affect the lethal toxicity of SLT-II for endotoxin-resistant C3H/HeJ mice. These results suggest that LPS enhances the effects of SLT-II in vivo. Since cecal changes that increase mucosal permeability occur in response to SLT in rabbits, this synergy may be directly relevant to disease processes.This publication has 17 references indexed in Scilit:
- Continuous Peritoneal Infusion of Shiga-like Toxin II (SLT II) as a Model for SLT II-Induced DiseasesThe Journal of Infectious Diseases, 1989
- The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infectionsHuman Pathology, 1988
- Inhibition of protein synthesis by a Vero toxin (VT2 or Shiga-like toxin II) produced by Escherichia coli O157:H7 at the level of elongation factor 1-dependent aminoacyl-tRNA binding to ribosomesMicrobial Pathogenesis, 1988
- The Histopathology of Rectosigmoid Biopsies from Adults with Bloody Diarrhea Due to Verotoxin-Producing Escherichia coliAmerican Journal of Clinical Pathology, 1987
- The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesisBiochemical Journal, 1987
- ENDOTOXINS AND DISEASE MECHANISMSAnnual Review of Medicine, 1987
- The Association Between Idiopathic Hemolytic Uremic Syndrome and Infection by Verotoxin-Producing Escherichia coliThe Journal of Infectious Diseases, 1985
- Observations on the Measurement and Evaluation of Endotoxemia by a Quantitative Limulus Lysate MicroassayThe Journal of Infectious Diseases, 1984
- Laboratory investigation of hemorrhagic colitis outbreaks associated with a rare Escherichia coli serotypeJournal of Clinical Microbiology, 1983
- Hemorrhagic Colitis Associated with a RareEscherichia coliSerotypeNew England Journal of Medicine, 1983